Epigenetics, the study of heritable changes in gene expression not involving DNA sequence alterations, plays a crucial role in cancer development. DNA methylation, a key epigenetic mechanism, influences gene activity and nuclear structure. In normal cells, CpG islands in gene regulatory regions are typically unmethylated, but hypermethylation of these regions can silence tumor suppressor genes, contributing to cancer. Hypermethylation of CpG islands in tumor suppressor gene promoters is a major event in cancer initiation, leading to gene inactivation and promoting tumorigenesis. Conversely, DNA hypomethylation can activate transposable elements and disrupt genomic stability, increasing the risk of cancer. Epigenetic changes also affect genomic imprinting, which is critical for normal development and can lead to cancer when disrupted. Histone modifications, such as acetylation and methylation, regulate gene expression and are involved in cancer progression. Aberrant histone modifications, including reduced acetylation and increased methylation, are associated with tumor suppressor gene silencing. Epigenetic alterations in cancer cells can be reversed using drugs that target DNA methylation or histone modifications, such as DNA demethylating agents and histone deacetylase inhibitors. These therapies have shown promise in clinical trials, particularly in cancers like leukemia and lymphoma. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are involved in cancer development. Epigenetic changes, such as DNA hypermethylation, can silence miRNA genes, leading to oncogenic effects. miRNA expression profiles are being explored as potential biomarkers for cancer diagnosis and prognosis. Epigenetic therapy is an emerging field with potential applications in cancer treatment, offering new strategies for targeting cancer cells through reversible epigenetic modifications. The study of epigenetics in cancer has led to the development of new diagnostic tools, prognostic markers, and therapeutic approaches, highlighting the importance of understanding the molecular origins of cancer through epigenetic mechanisms.Epigenetics, the study of heritable changes in gene expression not involving DNA sequence alterations, plays a crucial role in cancer development. DNA methylation, a key epigenetic mechanism, influences gene activity and nuclear structure. In normal cells, CpG islands in gene regulatory regions are typically unmethylated, but hypermethylation of these regions can silence tumor suppressor genes, contributing to cancer. Hypermethylation of CpG islands in tumor suppressor gene promoters is a major event in cancer initiation, leading to gene inactivation and promoting tumorigenesis. Conversely, DNA hypomethylation can activate transposable elements and disrupt genomic stability, increasing the risk of cancer. Epigenetic changes also affect genomic imprinting, which is critical for normal development and can lead to cancer when disrupted. Histone modifications, such as acetylation and methylation, regulate gene expression and are involved in cancer progression. Aberrant histone modifications, including reduced acetylation and increased methylation, are associated with tumor suppressor gene silencing. Epigenetic alterations in cancer cells can be reversed using drugs that target DNA methylation or histone modifications, such as DNA demethylating agents and histone deacetylase inhibitors. These therapies have shown promise in clinical trials, particularly in cancers like leukemia and lymphoma. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are involved in cancer development. Epigenetic changes, such as DNA hypermethylation, can silence miRNA genes, leading to oncogenic effects. miRNA expression profiles are being explored as potential biomarkers for cancer diagnosis and prognosis. Epigenetic therapy is an emerging field with potential applications in cancer treatment, offering new strategies for targeting cancer cells through reversible epigenetic modifications. The study of epigenetics in cancer has led to the development of new diagnostic tools, prognostic markers, and therapeutic approaches, highlighting the importance of understanding the molecular origins of cancer through epigenetic mechanisms.